News About: Pharm. Industry
Dong-A to have large-scale research complex
Dong-A Pharmaceutical Co. plans to establish another large-scale research complex at Sanggal by 2012 as part of its efforts to create new chemical entities.
Last July, the company reshuffled its three research inst...
Handok to introduce calfactant, acute respiratory distress syndrome treatmentHandok Pharm says it signed a licensing agreement with the US-based Pneuma Partners to distribute calfactant (trade name: Infasurf), a medication used to treat respiratory distr...
|
Multinationals challenge with new products
Multinational pharmaceutical firms are seeking to rock the domestic market with 20-odd new drugs, although the successful listing of these medicines into the national health insurance appears to be uncertain.
Pfize...
Drug makers call for consistent pharmaceuticals-related policy
Domestic pharmaceutical firms demanded the government establish more predictable and consistent regulations over pharmaceuticals with a sufficient grace period, which will become a key to sharpen their competitiveness...
Hwang named AZK CFOHwang Jung-wook, former Chief Financial Officer (CFO) of Pizza Hut Korea, has been appointed CFO of AstraZeneca Korea as of Jan. 1, 2008 to ensure its sustained growth and beef ...
|
Kolon Pharm appoints Lee as new presidentKolon Pharm said it appoints Lee Woo-suk as a new president as of January 1, 2008 as part of its efforts to boost its pharmaceutical business.
As a graduate of Seoul National...
|
Dong-A eyes unified distribution over 5 OTCs
Dong-A Pharmaceutical Co. plans to conduct a unified distribution for its five OTC products with larger market share, such as Panpyrin, Circulan, Bigen, Bigencreamton and Hanobac in an attempt to provide better pharma...
GCC aims for W520 billion sales
Green Cross Corporation says it is targeting 520 billion won in sales this year, compared with last year's 44.2 billion won.
The company will strengthen brand recognition of flagship prescription drugs from nasal-s...
KFDA approves Retisert for treatment of affecting posterior segment of eye
The Korea Food and Drug Administration says it has approved Bausch & Lomb's Retisert (fluocinolone acetonide) 0.59 mg, the world's first intravitreal drug implant for the treatment of chronic non-infectious uveitis af...
Han renamed KIT chief
Han Sang-seop, has been reappointed head of the Korea Institute of Toxicology (KIT) on January 1. He will assume the post until 2010.
KIT, under the wing of the Korea Research Institute of Chemical Technology, is i...
